Orally active adenosine kinase inhibitors
    1.
    发明授权
    Orally active adenosine kinase inhibitors 失效
    口服活性腺苷激酶抑制剂

    公开(公告)号:US5763597A

    公开(公告)日:1998-06-09

    申请号:US660506

    申请日:1996-06-07

    IPC分类号: C07H19/14 C07H19/16

    CPC分类号: C07H19/14

    摘要: This invention relates to adenosine kinase inhibitors and to nucleoside analogs, specifically to orally active, substituted 5-aryl pyrrolo�2,3-d! pyrimidine and 3-aryl pyrazolo�3,4-d! pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention also relates to the preparation and use of these and other adenosine kinase inhibitors in the treatment of cardiovascular and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.

    摘要翻译: 本发明涉及腺苷激酶抑制剂和核苷类似物,特别是具有作为腺苷激酶活性的口服活性的取代的5-芳基吡咯并[2,3-d]嘧啶和3-芳基吡唑并[3,4-d]嘧啶核苷类似物 抑制剂。 本发明还涉及这些和其它腺苷激酶抑制剂在治疗心血管和脑血管疾病,炎症等疾病中的制备和应用,可以通过增加腺苷的局部浓度来调节。

    C-4' modified adenosine kinase inhibitors
    7.
    发明授权
    C-4' modified adenosine kinase inhibitors 失效
    C-4'修饰的腺苷激酶抑制剂

    公开(公告)号:US5763596A

    公开(公告)日:1998-06-09

    申请号:US660505

    申请日:1996-06-07

    IPC分类号: C07H19/044

    CPC分类号: C07H19/044

    摘要: This invention relates to adenosine kinase inhibitors and to nucleoside analogs, C-4' modified pyrrolo�2,3-d!pyrimidine and pyrazolo�3,4-d!pyrimidine nucleoside analogs having activity as adenosine kinase inhibitors. The invention relates to nucleoside analogs of this kind, having zero substitutions or two substitutions at the C-4' position of the furanose (sugar) moiety. The invention also relates to the preparation and use of these adenosine kinase inhibitors in the treatment of cardiovascular, and cerebrovascular diseases, inflammation and other diseases which can be regulated by increasing the local concentration of adenosine.

    摘要翻译: 本发明涉及具有作为腺苷激酶抑制剂活性的腺苷激酶抑制剂和核苷类似物C-4'修饰的吡咯并[2,3-d]嘧啶和吡唑并[3,4-d]嘧啶核苷类似物。 本发明涉及这样的核苷类似物,其在呋喃糖(糖)部分的C-4'位置具有零取代或两个取代。 本发明还涉及这些腺苷激酶抑制剂在治疗心血管和脑血管疾病,炎症等疾病中的制备和应用,可以通过增加腺苷的局部浓度来调节。